Building on the specific lipid expertise of their Boston-based affiliate Organix, Symeres, a leading transatlantic CRO and CDMO, extends its drug discovery and development services with the production of lipids under GMP. With the development of novel mRNA-based therapeutics, there has been a rapid increase in the development of novel lipids and lipid technologies, especially since the outbreak of the COVID-19 pandemic. Symeres has been supporting the global pharma and biotech industry with the synthesis and ultrapurification of these novel lipids.

Typically, mRNA-based vaccines rely on a lipid formulation to ensure stability and intracellular delivery. As a result, research centered around novel lipids has flourished. Lipid-based formulations of these biopharmaceuticals may provide better specificity for increased immune response and possible dose reduction. There is strong demand for novel, high-quality lipids for drug delivery.

Symeres/Organix has over two decades of experience in the design, synthesis, and purification of novel lipids, with wide variations in structural motifs, including aliphatic chain lengths, branching, number of C=C bonds, polar head groups, stereogenic centers, sugars, and PEGs. High-purity materials can be obtained by automated (reverse-phase) chromatography, preparative HPLC/SFC purification systems equipped with ELSD and CAD detection, or by crystallization techniques for salt intermediates. All necessary analytical techniques are available at Symeres sites in the USA and Europe, including the quality framework to secure high-performance lipid development and GMP production.

Also, thanks to the two decades of experience of Symeres and Organix, some of the lipids are available directly from our stock catalogue.